Pharma stock engaged in the business of manufacturing and trading Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic commodities, formulations, and many more hit a 5 percent upper circuit in the day’s trade following the announcement to issue bonus shares of the company.
Price Action
With a market capitalization of Rs. 51 Crores, the shares of Walpar Nutritions Limited hit a 5 percent upper circuit at Rs. 109.80 per equity share, from its previous day’s close price of Rs. 104.60.
What happened
The Board of Directors of Walpar Nutritions Limited are going to meet on July 5, 2024, to consider and approve the issue of bonus equity shares of the company with a face value of Rs. 10, to the company’s shareholders as on the record date and other related matters.
About the company
Walpar Nutritions Limited is engaged in the business of manufacturing and trading Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic commodities, formulations, and ingredients
It is a specialized Contract manufacturer of different formulations of Nutraceuticals and Herbal products. It manufactures private label brands for different companies and sells its own brands, through online and direct channels.
Its product portfolio consists of General Nutritional Supplements, Functional Foods, Sports Nutrition, Herbal Supplements, Ayurvedic Proprietary Medicine, Oral Sprays, Sustained-Release Tablets, Delayed-Release Capsules, Oral Concentrated Solutions, Protein Powders, and many more.
Financials and Ratios
Its revenue from operations grew by 78 percent from Rs. 35.14 Crores in FY23 to Rs. 62.52 Crores in FY24, accompanied by profits of Rs. 81 Lakhs to Rs. 1.94 Crores.
In terms of return ratios, it has reported a return on equity (ROE) of 13.5 percent and a return on capital employed (ROCE) of 13.2 percent. It has reported a debt-to-equity ratio of 0.59.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
